European Notebook: Revolutionary Change Needed for European Biotech; CHMP Releases Opinions Agenda; Growing Interest In Biosimilars
Executive Summary
Radical change urged to help Europe compete in biotech; CHMP becomes less secretive over its meeting agendas; Almirall restructures its European business and buys U.S. dermatology business; biosimilar biologics companies, Almotech and Samsung Bioepis, target Europe.
You may also be interested in...
Clinical Trials Transparency: EMA Delay Gives Industry Initiative More Time To Take Root
EMA’s plans for access to clinical trials data not set to be ready until well into 2014.
Germany’s Grand Coalition Offers Pharma Little Certainty, Except For Continued Discounts
Germany’s new grand coalition government includes a health minister with no background in health care.
Bayer Chief: Pharma’s Bad Rep Puts Europe Drug Business Model At Risk
Bayer‘s Chairman Marijn Dekkers says the pharma sector’s poor public reputation and consequent loss of faith in the industry risks destroying the European drug business model.